Skip to content
Medical Health Aged Care, Political

Minns ministers must stop misleading on paramedic pay

Health Services Union < 1 mins read

The Minns government is misleading the public with deliberately inflated figures about what paramedics are paid, as it risks mass resignation and deregistration of one of its most skilled but underpaid workforces.

In a note circulated to media, the Government has claimed its pay offer would lift a first year paramedic’s take home pay from $123,594 to $137,683.

This is not a figure that has been put to the HSU and nor it accurate. The offer put to the Union proposes a paltry 11.4 per cent, four year increase to the base pay of first year paramedics, from $74,364 to $82,877.

The so-called ‘take home’ pay figure quoted to media for a year six paramedic of $132,544 is also inaccurate.

Under the increase the Government actually has proposed - a 25.8 per cent /four year increase to base pay of a year six paramedic - NSW paramedics would still be paid at least six per cent less than their Queensland colleagues.

“The people of NSW need and deserve an ambulance workforce they can rely upon. Unfortunately, the workforce is crumbling. Paramedics literally can’t afford to keep doing their jobs," HSU NSW Secretary Gerard Hayes said. 

“The inadequate offer we received this morning does not fix the problem. Under this proposal we will never catch up with Queensland. And that means paramedics will just keep leaving.

“More than 500 paramedics have left NSW in the last six months. Many hundreds more will leave in the next six months.

“Paramedics are more than ambulance drivers. While politicians pose and preen, paramedics save lives.  They earn a  base salary of $79,000 while a back bench MP earns 100k more."

The HSU pay claim in this dispute is a 20 per cent catch up to achieve parity with Queensland, additional to whatever base public sector pay rise exists at the time.

Inquiries: Nick Lucchinelli 0422229032

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.